SH3RF3-AS1: A Potential Drug Target and Biomarker (G100287216)

Target Name: SH3RF3-AS1

NCBI ID: G100287216

SH3RF3-AS1

Other Name(s): SH3RF3 antisense RNA 1

SH3RF3-AS1: A Potential Drug Target and Biomarker

SH3RF3-AS1, also known as SIRT3, is a non-protein coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and aging. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug has led to a growing interest in the field of pharmacology.

SH3RF3-AS1 is a small non-coding RNA molecule that consists of 23 amino acid residues. It is expressed in various tissues and cells in the body and is involved in various cellular processes, including DNA replication, gene expression, and stress response. One of its unique features is its ability to interact with other RNA molecules, including microRNA (miRNA) and long non-coding RNA (lncRNA), to regulate their stability and function.

Recent studies have identified SH3RF3-AS1 as a potential drug target due to its involvement in various cellular processes that are associated with the development and progression of diseases. For example, SH3RF3-AS1 has been shown to play a role in the regulation of cell apoptosis, which is a natural process that helps the body eliminate damaged or dysfunctional cells. In addition, SH3RF3-AS1 has been linked to the regulation of cellular processes that are associated with aging, such as the accumulation of misfolded proteins and the decline in cellular repair mechanisms.

As a potential drug target, SH3RF3-AS1 has the potential to treat a wide range of diseases, including cancer, neurodegenerative diseases, and aging. For example, SH3RF3-AS1 has been shown to be downregulated in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that targeting SH3RF3-AS1 may be an effective way to treat these diseases. In addition, SH3RF3-AS1 has been linked to the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Targeting SH3RF3-AS1 in these diseases may be a promising approach to develop new treatments.

As a potential biomarker, SH3RF3-AS1 has the potential to diagnose and monitor a wide range of diseases. For example, SH3RF3-AS1 has been shown to be downregulated in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that SH3RF3-AS1 may be a useful biomarker for these diseases. In addition, SH3RF3-AS1 has been linked to the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Monitoring SH3RF3-AS1 levels in individuals with these diseases may be a promising approach to diagnose and treat them.

In conclusion, SH3RF3-AS1 is a unique RNA molecule that has the potential to be a drug target and biomarker for various diseases. Its ability to interact with other RNA molecules and its involvement in various cellular processes make it an attractive target for researchers to investigate. Further studies are needed to fully understand the role of SH3RF3-AS1 in disease and to develop effective treatments.

Protein Name: SH3RF3 Antisense RNA 1

The "SH3RF3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH3RF3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets